NAMS
NewAmsterdam Pharma Company NV

467
Mkt Cap
$3.5B
Volume
883,676.00
52W High
$42.00
52W Low
$14.06
PE Ratio
-17.41
NAMS Fundamentals
Price
$31.18
Prev Close
$30.41
Open
$30.40
50D MA
$33.97
Beta
0.97
Avg. Volume
715,394.98
EPS (Annual)
-$1.72
P/B
5.09
Rev/Employee
$225,030.00
$3,516.96
Loading...
Loading...
News
all
press releases
NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CEO Michael Davidson sold 443,707 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume Increase - Still a Buy?
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume - Time to Buy...
MarketBeat·3d ago
News Placeholder
Handelsbanken Fonder AB Boosts Stake in NewAmsterdam Pharma Company N.V. $NAMS
Handelsbanken Fonder AB raised its stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 18.8% during the third quarter, according to the company in its most recent 13F...
MarketBeat·3d ago
News Placeholder
JPMorgan Chase & Co. Has $37.04 Million Position in NewAmsterdam Pharma Company N.V. $NAMS
JPMorgan Chase & Co. lessened its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 10.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The...
MarketBeat·5d ago
News Placeholder
NewAmsterdam Pharma (NASDAQ:NAMS) CEO Michael Davidson Sells 58,253 Shares
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CEO Michael Davidson sold 58,253 shares of the company's stock in a transaction on Wednesday, February 25th. The shares were sold at...
MarketBeat·6d ago
News Placeholder
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells 58,253 Shares of Stock
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CEO Michael Davidson sold 58,253 shares of the company's stock in a transaction dated Wednesday, February 25th. The shares were sold...
MarketBeat·6d ago
News Placeholder
NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $2,339,194.20 in Stock
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CEO Michael Davidson sold 64,708 shares of the firm's stock in a transaction dated Tuesday, February 24th. The shares were sold at an...
MarketBeat·6d ago
News Placeholder
Michael Davidson Sells 183,332 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CEO Michael Davidson sold 183,332 shares of the stock in a transaction on Thursday, February 26th. The stock was sold at an average...
MarketBeat·6d ago
News Placeholder
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 45,481 Shares of Stock
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 45,481 shares of the company's stock in a transaction dated Friday, February 20th. The...
MarketBeat·8d ago
News Placeholder
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twelve research firms that are presently covering the...
MarketBeat·9d ago
<
1
2
...
>

Latest NAMS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.